Clinical Trials Logo

Arthritis, Gouty clinical trials

View clinical trials related to Arthritis, Gouty.

Filter by:

NCT ID: NCT01356602 Completed - Clinical trials for Acute Gouty Arthritis

Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

Start date: May 2011
Phase: Phase 3
Study type: Interventional

This study assessed the safety and efficacy of canakinumab pre-filled syringes in comparison to triamcinolone acetonide 40 mg and canakinumab lyophilizate in patients that have frequent flares of acute gouty arthritis.

NCT ID: NCT00927810 Completed - Gouty Arthritis Clinical Trials

Long Term Study of Canakinumab (ACZ885) in Patients With Gout

Start date: June 5, 2009
Phase: Phase 2
Study type: Interventional

This 24-week open-label extension study is designed to provide additional long-term safety data up to a total of 1-year for patients rolling over from the core study, and to collect further efficacy and tolerability data for all the patients, irrespective whether they have an acute flare of gout or not. Patients will be treated on demand with canakinumab (ACZ885) in this extension study.

NCT ID: NCT00663169 Completed - Arthritis, Gouty Clinical Trials

Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout

Start date: April 2008
Phase: Phase 2
Study type: Interventional

This is an exploratory proof-of-concept study to evaluate the safety and efficacy of canakinumab (ACZ885) for inflammation and pain associated with acute gouty arthritis.

NCT ID: NCT00549549 Completed - Arthritis, Gouty Clinical Trials

Celebrex In Acute Gouty Arthritis Study

Start date: February 2008
Phase: Phase 3
Study type: Interventional

This is a multicenter, double-blind, double-dummy, randomized, active-controlled study that will include an 8-day treatment period followed by a 1-week follow-up period in patients experiencing symptoms of an acute exacerbation of gouty arthritis.

NCT ID: NCT00170781 Completed - Clinical trials for Acute Gouty Arthritis

Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout

Start date: June 2005
Phase: Phase 4
Study type: Interventional

This study is designed to develop our understanding of the efficacy and safety of using lumiracoxib in the treatment of patients with acute gout. This is a multi-center, double-blind, randomized, parallel group study comparing a single daily dose of 400 mg lumiracoxib with the established dose of indomethacin 50 mg taken three times a day in terms of efficacy

NCT ID: NCT00142558 Completed - Acute Gout Clinical Trials

A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED)

Start date: January 1, 2005
Phase: Phase 4
Study type: Interventional

A study to evaluate the effects of etoricoxib and indomethacin in the treatment of acute gout.